• The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF

  NCT04682600

  CompletedInterventionalNot ApplicableUpdated Jul 20, 2026
• Validation of the New Vibration-guided FibroScan Examination

  NCT05567328

  CompletedInterventionalNot ApplicableUpdated Jan 15, 2025
• Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound

  NCT02044523

  CompletedObservationalUpdated Sep 20, 2018
• Combining MRI Steatosis Assessment and Transient Elastography to Improve Liver Fibrosis Diagnosis in Non Alcoholic Fatty Liver Disease

  NCT03245606

  CompletedObservationalUpdated Jul 14, 2020
• Quantitative Ultrasound With Liver Incytes for Evaluation of Non-Alcoholic Fatty Liver Disease

  NCT04576923

  TerminatedInterventionalNot ApplicableUpdated Aug 21, 2023
• FibroScan-Reproducibility and Repeatability Study

  NCT06877026

  CompletedInterventionalNot ApplicableUpdated Apr 13, 2026

ClinicalTrials.gov ID

NCT05908006

Lead Sponsor

GI AllianceOTHER

Overall Status

Unknown status

Study Type

Observational

Enrollment

100Estimated

Last Update Posted

Jun 18, 2023Actual

Start Date

Jul 15, 2023Estimated

Primary Completion Date

Dec 30, 2023Estimated

Completion Date

Jan 31, 2024Estimated

Official Title

Comparison of Steatosis and Fibrosis Measurements From Velacur and MRE/MRI-PDFF in Patients With Chronic Liver Disease

Brief Summary

The goal of this open-label, non-randomized, prospective study is to compare Velacur and MRE in all sexes, 18-80 years old with Non-Alcoholic Fatty Liver Disease (NAFLD). The main aims is to:

• Validate the use of Velacur and elastography cut offs in a patient cohort with all types of chronic liver disease, against MRE results for fibrosis staging.
• Validate the use of Velacur and attenuation cut offs in a patient cohort with all types of chronic liver disease, against MRI-PDFF results for steatosis staging.

Participants will Study participants will attend 1 study visit, in which measurement of liver stiffness with Velacur and FibroScan, will be performed by a certified technician. As part of Visit 1, Patients will also complete an MRI exam which will include both MRE and MRI-PDFF measurements (MRI imaging can take place within 28 days of the Velacur scan).

Detailed Description

This will be a prospective, open label, validation study of the Velacur system in comparison to MRE and MRI-PDFF in patients with liver disease or suspected liver disease.

Approximately 100 subjects may be enrolled in this study. Participants should span all levels of fibrosis and steatosis.

The study is comprised of: Screening Period (up to 8 days) and Visit 1. There are no safety follow-up visits in this study.

The primary objective of the study is to compare the results of Velacur against MRE and MRI-PDFF results for liver stiffness and steatosis. As part of prior studies, using MRE as the gold standard, clinical cut-off for Velacur have been developed. The primary objective of this study is to validate these cut-offs to see if Velacur can correctly classify patients.

Secondary objectives include correlating the stiffness and attenuation results of Velacur with other clinical measures of fibrosis and steatosis such as Fib-4, and correlations with other clinical measurements collected through clinical care or clinical trials, such as Enhance Liver Fibrosis (ELF) test, FibroScan, MRI, or ultrasound based shear wave elastography (SWE) as they are available.

• Non-alcoholic Fatty Liver Disease (NAFLD)

• Velacur

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

Patients with evidence of NAFLD or other chronic liver disease such as one of the following:

Biopsy proven chronic liver disease OR

Evidence of hepatic steatosis or chronic liver disease on non-invasive assessment by one or more of the following criteria:

• Abdominal ultrasound within 12 months
• MRI-PDFF (greater than 12%) within 12 months
• FibroScan CAP score > 230 dB/m within 12 months OR At least 2 criteria for metabolic syndrome and increased stiffness on FibroScan (>8kPa) within 12 months

Exclusion Criteria:

• BMI greater than 40 kg/m2 (or unable to fit into MRI bore)
• Subject with current, significant alcohol consumption or history of significant alcohol consumption
• Subjects with evidence of decompensated liver disease

Observational Model

Case-Only

Time Perspective

Prospective

Lead Sponsor

GI AllianceOTHER

Collaborators

Sonic IncytesINDUSTRY

Tessa.Kus@GIAlliance.com281-699-1715